Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuelle Ferrant

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Haematologica|December 22, 2022
Retrospective analysis of a cohort of 41 <i>de novo</i> B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study)Caroline Algrin, Louis Pérol, Elise Chapiro, et al.
Journal of Geriatric Oncology|June 17, 2026
Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi settingPaolo Ghia, Davide Rossi, Emmanuelle Ferrant, et al.
European Journal of Human Genetics : EJHG|December 5, 2013
Development of primary early-onset colorectal cancers due to biallelic mutations of the FANCD1/BRCA2 geneEmilie Degrolard-Courcet, Joanna Sokolowska, Marie-Martine Padeano, et al.
Nature Communications|August 9, 2024
Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trialRomain Guièze, Loïc Ysebaert, Damien Roos-Weil, et al.
Leukemia|January 2, 2022
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemiaJeff P Sharman, Miklos Egyed, Wojciech Jurczak, et al.
Leukemia|December 3, 2024
Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemiaJeff P Sharman, Miklos Egyed, Wojciech Jurczak, et al.
Clinical Nuclear Medicine|June 11, 2021
Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T CellsPierre Sesques, Jérémie Tordo, Emmanuelle Ferrant, et al.
American Journal of Hematology|August 4, 2020
Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European centerPierre Sesques, Emmanuelle Ferrant, Violaine Safar, et al.
Blood Advances|April 7, 2023
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trialAnne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier, et al.
Eclinicalmedicine|January 8, 2026
Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO groupAnne Quinquenel, Rémi Letestu, Magali Le Garff-Tavernier, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Haematologica|December 22, 2022
Retrospective analysis of a cohort of 41 <i>de novo</i> B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study)Caroline Algrin, Louis Pérol, Elise Chapiro, et al.
Journal of Geriatric Oncology|June 17, 2026
Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi settingPaolo Ghia, Davide Rossi, Emmanuelle Ferrant, et al.
European Journal of Human Genetics : EJHG|December 5, 2013
Development of primary early-onset colorectal cancers due to biallelic mutations of the FANCD1/BRCA2 geneEmilie Degrolard-Courcet, Joanna Sokolowska, Marie-Martine Padeano, et al.
Nature Communications|August 9, 2024
Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trialRomain Guièze, Loïc Ysebaert, Damien Roos-Weil, et al.
Leukemia|January 2, 2022
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemiaJeff P Sharman, Miklos Egyed, Wojciech Jurczak, et al.
Leukemia|December 3, 2024
Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemiaJeff P Sharman, Miklos Egyed, Wojciech Jurczak, et al.
Clinical Nuclear Medicine|June 11, 2021
Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T CellsPierre Sesques, Jérémie Tordo, Emmanuelle Ferrant, et al.
American Journal of Hematology|August 4, 2020
Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European centerPierre Sesques, Emmanuelle Ferrant, Violaine Safar, et al.
Blood Advances|April 7, 2023
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trialAnne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier, et al.
Eclinicalmedicine|January 8, 2026
Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO groupAnne Quinquenel, Rémi Letestu, Magali Le Garff-Tavernier, et al.
Pageof 5